Compare iShares Core MSCI EAFE ETF (IEFA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs TG Therapeutics Inc — how do they compare? iShares Core MSCI EAFE ETF trades at $96.52 (market cap $189.19B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 23.2× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, iShares Core MSCI EAFE ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 40 Days and TG Therapeutics Inc for 16 Days on average.
| IEFA | TGTX | |
|---|---|---|
Market Cap | $189.19B | $8.16B |
Volume | 8,441,787 | 1,735,121 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $59.06 |
52-Week Low | $85.06 | $26.94 |
Typical Hold Time | 40 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA, the iShares Core MSCI EAFE ETF, trades at $95.87, down 0.34% on the day, with a bearish technical signal driven by moving averages and oscillators. The fund provides exposure to developed markets outside North America, managing $196 billion in assets. Recent news highlights comparisons with competing international ETFs, noting its higher dividend yield and lower costs relative to some peers, though it has underperformed others on a total return basis over the past year.
The outlook for IEFA is mixed, offering diversification benefits and income through dividends but facing headwinds from weaker relative performance and bearish technical momentum. Key risks include concentration in developed markets, which may lag during global growth shifts, and expense ratio competition. Analyst sentiment is cautious due to recent underperformance versus broader global funds.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
